- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr2.97 (+3.31%)Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr5.73 (-10.26%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr6.06 (-1.29%)Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr6.11Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.05 (-3.37%)Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr6.61 (+0.75%)Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr6.67 (+3.83%)Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr6.54 (+1.01%)Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr6.84 (+1.21%)Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr7.66 (+1.85%)Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr8.47 (-4.26%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr6.55 (+1.27%)Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr6.88 (+0.84%)Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr9.15 (-0.73%)Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr9.55 (+1.57%)Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr10.05 (-4.96%)Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr9.74 (-0.14%)Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr14.77 (+2.09%)Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr16.15 (-1.64%)Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr11.95 (+2.19%)Earnings
Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call Transcript
This call is being recorded. Welcome to Medivir press conference. For the first part of the conference call, the participants will be in listen only mode. (Operator Instructions) Now I will hand the conference over to CEO, Jens Lindberg. Please go ahead.
Thank you. Good afternoon, and welcome, everyone. My name is Jens Lindberg, I'm the CEO of Medivir. I am joined for today's call by our Chief Medical Officer, Pia Baumann, as well as our Chief Scientific Officer, Fredrik Ãberg, and Magnus Christensen, our CFO. Today's call, we will follow up on the events at last week when we presented our first data for fostrox + Lenvima at a scientific congress at ASCO GI in San Francisco. And go through the data, and also what that means, implications for our plans going forward.
So we are now back in Sweden after a very energizing week with a lot of interactions with global experts in the field of hepatocellular carcinoma. And in the call today, we will focus on three elements. We'll start off with a bit of a sort
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)